AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
Zacks Investment Research
AbbVie (ABBV) signs an exclusive global licensing deal with the Chinese company FutureGen to develop FG-M701, a next-generation TL1A antibody, for IBD indications.
Continue Reading